Trial Profile
Multi-Center Phase II Clinical Trial on Efficacy and Safety of Interferon Alfa-n1 + Sorafenib Combination Therapy in Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha-n1; Interferon alpha-n1
- Indications Renal cancer
- Focus Therapeutic Use
- 08 Mar 2013 Planned end date changed from 1 Dec 2013 to 30 Sep 2013 as reported by University Hospital Medical Information Network - Japan.
- 08 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 09 May 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by University Hospital Medical Information Network - Japan.